Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma Leukemia (2005) The use of thalidomide has improved the treatment of patients with multiple myeloma (MM). Thalidomide has shown to have therapeutic activity as a single agent in patients with relapsed and/or refractory MM. 1, 2 Thalidomide monotherapy can induce remissions in about one-third of relapsing or refractory patients 1, 2, [4] [5] [6] [7] [8] and combinations of thalidomide with dexamethasone and/or chemotherapy can further improve response rates in these patients. [1] [2] [3] Abnormal cytogenetics, high plasma cell labeling index, IgA isotype, high levels of LDH or beta2-microglobulin as well as low hemoglobulin, platelet count or albumin have been identified in different studies as adverse prognostic factors for outcome after treatment with thalidomide in patients with relapsed or refractory MM. [4] [5] [6] [7] [8] Apart from results of patients with advanced and heavily pretreated disease, studies have shown efficiency of thalidomide treatment in untreated patients. 1, 2 Currently, data of an early patient population, who are neither untreated nor heavily pretreated, are very limited. Several groups have studied patients with relapsed or refractory MM, 1,2,4-8 but the patient populations were widely heterogeneous including patients with first relapse and patients with later relapse after more than 5 years of prior therapy. Patients with relapse off treatment, primary refractory disease and refractory relapse were mixed as well as patients with prior high-dose chemotherapy (HDT) and patients who had received only conventional chemotherapy. Thus, it is very difficult to define the role of thalidomide for the individual patient.
The objective of our study was to assess treatment response and prognosis of a well-defined patient population. Therefore, we performed a single center retrospective analysis including patients with the following characteristics: (1) patients who received front-line HDT, (2) patients who were not refractory to front-line therapy but obtained at least a minimal response and (3) patients who received thalidomide as a single agent at first, untreated relapse. We show that this early patient group has a favorable outcome in comparison to results of mixed patient groups with advanced myeloma. Further, we provide prognostic factors for this group of patients, identifying a subgroup of patients with bad risk and need for a more aggressive salvage therapy. This will help to optimize the clinical use of thalidomide in patients with MM relapsing after HDT.
The objectives of our study were to determine response rate, progression-free survival (PFS) and overall survival (OS) and to identify relevant prognostic factors for this group of patients. Treatment response and duration of remissions were assessed according to the EBMT criteria. For the evaluation of prognostic parameters, the following data have been examined: age (no older than 65 years vs older than 65 years), gender (male vs female), immunoglobulin isotype (no IgA isotype vs IgA isotype), results from conventional cytogenetic banding analysis of bone marrow samples obtained prior to thalidomide therapy (normal vs abnormal), results from laboratory tests obtained at the time of relapse including level of serum beta2-microglobulin (p2.5 vs 42.5 mg/dl), serum LDH (p0.8 Â normal limit vs 40.8 Â normal limit), serum CRP (p6 vs 46 mg/l), serum albumin level (p40 vs 440 g/l), platelet count (4100 Â 10 9 /l vs p100 Â 10 9 /l), hemoglobulin (410 mg/l vs p10 mg/dl) and serum creatinine (normal vs abnormal). Further, thalidomide dosage within the first 3 months (more than 200 mg daily vs 200 mg daily or less), HDT conditioning regimen (idarubicine/ melphalan/cyclophosphamide vs melphalan), response to HDT (complete remission (CR) þ near-complete remission (nCR) vs partial remission (PR) þ minimal response (MR)), duration of remission after HDT (412 vs o12 months) and application of interferon (INF) maintenance therapy after HDT (yes vs no) were included.
A total of 32 patients were included in this study. All patients had stage III disease, 31% had abnormal creatinine levels, 72% had IgG, 16% IgA and 12% other, nonsecretory isotype or light chain disease. The median age at the beginning of thalidomide treatment was 55 years (range: 33-67).The median beta2-microglobulin level was 2.7 mg/dl (range: 1.5-32.6), median LDH was 151 U/l (range: 97-234), median CRP was 5 mg/l (range: 3-33), median serum albumin was 4.4 g/l (range: 3.7-5.2), median platelet count was 167 Â 10 9 /l (range: 20-326), median hemoglobulin was 12 mg/dl (range: 7.3-14.7) and median creatinine was 1.0 mg/dl (range: 0.7-2.2). At the beginning of thalidomide therapy, cytogenetic conventional banding analysis was performed in 29 of 32 patients and showed an abnormal karyotype in 37% of patients. Prior therapy consisted of front-line HDT with or without INF maintenance therapy. The median time from diagnosis of stage III disease to HDT was 4 months (range: 3-13). Prior HDT conditioning regimen consisted either of idarubicin 42 mg/m 2 , melphalan 200 mg/m 2 and cyclophosphamide 120 mg/kg (HD-IMC, n ¼ 9) or melphalan 200 mg/m 2 (HD-M, n ¼ 23). INF alfa maintenance therapy was started after hematological reconstitution with a dosage of 1-4.5 million U in 22 patients and seven patients received no maintenance therapy after HDT. Response rates after HDT were as follows: 25% achieved a CR or an nCR, 69% a PR and 6% an MR. Duration of response lasted longer than 12 months in 69% of patients. The median PFS and OS after HDT was 22.0 (range 3.0-59.0) and 75.9 (range: 7.0-89.0) months, respectively.
At the time of relapse after HDT, all patients received salvage therapy with thalidomide as a single agent. Daily doses were individually escalated based on tolerance, ranging from 100 to 400 mg. Treatment was begun with 100 mg and dose escalations or reductions of thalidomide by 100 mg/day were scheduled at weekly intervals. The maximum-tolerated dosage was 400 mg and the median-tolerated dosage for maintenance therapy was 200 mg.
Overall response rate (XMR) in our study was 78%. Of 32 patients, 59% (95% CI 41-80%) achieved a PR and 19% (95% CI 7-40%) an MR. No patient achieved a CR, but one patient achieved an nCR. Six patients (19% (95% CI 7-40%)) had SD with no disease progression within at least 3 months after the start of thalidomide treatment. One patient was primary refractory to thalidomide. After a median follow-up of 24 months (range: 3-64), the median PFS after start of treatment with thalidomide was 23.4 months (range: 2.1-40.4) and the median survival was 41.3 months (range: 3-64) ( Figure 1 ).
According to univariate analysis (Kaplan-Meier estimates, log rank), predictive factors for a superior PFS after thalidomide treatment were normal cytogenetics (P ¼ 0.08), CRP level p6 mg/l (P ¼ 0.02), platelet count 4100 Â 10 9 /l (P ¼ 0.0002), hemoglobulin 410 mg/l (P ¼ 0.005) and duration of remission after the previous HDT lasting more than 12 months (P ¼ 0.02). On multivariate analysis (Cox's regression, including factors with log rank Po0.1 in unifactor analysis), normal cytogenetics (relative risk (RR) 6.5, P ¼ 0.01), CRP lower than 6 mg/l (RR 7.0, P ¼ 0.01) and duration of remission after HDT of more than 12 months (RR 4.5, P ¼ 0.05) were associated with a better outcome. Prognostic factors that significantly predicted superior OS in univariate analysis were serum albumin level (P ¼ 0.01), hemoglobulin (P ¼ 0.0002) and duration of remission after HDT (P ¼ 0.001). Duration of remission after HDT was the only predictive factor for OS in a multivariate analysis (RR 5.5, P ¼ 0.01). Thus, patients with long-lasting remissions after HDT also had sustained remissions during thalidomide treatment, whereas patients with early relapse within 12 months after HDT also had short-lasting remissions with thalidomide therapy. A prior remission after HDT lasting more than 12 months vs less than 12 months was associated with a median PFS and OS of 28 vs 6 (P ¼ 0.02) and 48 vs 18 months (Po0.01), respectively ( Figure 1 ). No single parameter was predictive for response to treatment with thalidomide.
The response rate (XPR) in our study population was 59%, which is superior to published studies with single-agent thalidomide and heavily pretreated patients where responses could be observed in about one-third of patients.
1,2,4-8 The median PFS in our patient population was 23 months, which is comparable to studies with untreated patients and superior to results from studies with single-agent thalidomide and patients with advanced myeloma, where PFS normally ranges between 6 and 13 months.
1,2,4-8 This finding suggests a higher efficiency of thalidomide therapy when used early during the disease. Our results show that for patients with first untreated relapse after HDT, single-agent thalidomide provides sufficient disease control without the need for more toxic combination therapies. This is in contrast to patients who suffer from relapse at a more advanced phase of their disease or who have refractory disease where inferior responses were observed with single-agent thalidomide.
1,2,4-8 These patients need a more toxic combination therapy of thalidomide with dexamethasone and chemotherapy, which is associated with higher toxicity. [1] [2] [3] Even though thalidomide has been shown to be very effective in our study population, we could identify a subgroup of patients with a high risk of relapse. An important finding of this study was that patients who relapsed within the first year after HDT had an inferior outcome in comparison to patients who had remissions lasting more than 12 months. This finding was consistent with both PFS and OS and could be confirmed by multivariate analysis. Interestingly, the duration of remission after HDT but not the quality of response after HDT was associated with outcome. Achievement of a CR or an nCR after HDT was not of prognostic relevance for the outcome of thalidomide salvage therapy. Instead, the duration of remission, irrespective of achievement of a CR, PR or an MR, had a prognostic impact. This suggests the existence of two faces of MM with a different biological behavior. Some patients with a 'malignant myeloma' subtype achieve responses that actually can be as pronounced as a CR, but the response lasts for only a short period of time. For these patients, response to therapy is not durable either after chemotherapy or after treatment with immunomodulatory drugs such as thalidomide. As a consequence, these patients should be treated with more aggressive combination therapies. Other patients achieve responses that may be only minor, but of long duration. In these patients, long-term impairment of myeloma cell growth can be achieved either by chemotherapy or immunomodulatory drugs. These patients are candidates for less toxic monotherapies.
In addition to the duration of prior remission, we have confirmed cytogenetics and CRP level as other important independent prognostic parameters. 4 Other factors, like low hemoglobulin, low platelet count or low serum albumin, 5, 6 were confirmed in our study as adverse prognostic factors by univariate analysis. Interestingly, the cumulative dose of thalidomide within the first 3 months of treatment was not predictive for response or outcome in our study. Some authors have suggested before that there is no dose-response relationship with thalidomide, 9, 10 which is in contrast to others [4] [5] [6] who showed that patients with a cumulative dosage of more than 32 or 42 g had a superior outcome. Patients in our study received a maximum of 32 g thalidomide within the first 3 months, and a cutoff level of 18 g was used for analysis. This lower dosage may be the cause that we did not find statistically differences in our study. Advanced age was not a bad prognostic factor in our patient population as has been shown by Mileshkin et al. 8 One reason for this may be that older patients in a mixed study population of patients with advanced disease may have received more intensive treatment than younger patients. Moreover, the older patients in that study mostly received conventional chemotherapy and were not considered candidates for HDT.
In conclusion, we show that patients with first relapse from remission after front-line HDT are candidates for single-agent thalidomide therapy. Two-thirds of this early patient group achieve durable remissions. Patients with early relapse after HDT, abnormal cytogenetics and high CRP level do not benefit from thalidomide monotherapy and should be treated with more aggressive combination therapies or novel agents. Raji is the first continuous human cell line of hematopoietic origin 1 and was derived 40 years ago from a Nigerian patient with Burkitt's lymphoma (BL). 2 Cell lines of BL origin were soon thereafter found to harbor the Epstein-Barr virus (EBV), leading to the discovery and isolation of this virus. 3 Subsequent studies revealed specific chromosome translocations, involving the heavy-or light-chain immunoglobulin gene loci on chromosome 14 or 2, and the c-myc oncogene locus on chromosome 8, in biopsies and cell lines of BL origin (for a review, see Klein 4 ). BL-derived cell lines provide a convenient and renewable source of material for genetic analysis, and they have been used in a broad variety of investigations, as reported in Leukemia 5 and elsewhere; however, classical G-banding techniques have failed to produce a complete picture of chromosomal abnormalities in these cells. In view of the wide interest in these cell lines (more than 2500 publications in the MedLine database on Raji alone since Pulvertaft's seminal report 2 ), we set out to resolve the definitive cytogenetic profile of the Raji cell line.
We thus performed molecular cytogenetic characterization of Raji cells using a combination of spectral karyotyping (SKY), array comparative genomic hybridization (CGH), and fluorescence in situ hybridization (FISH) techniques. Cells were obtained from the tissue culture collection of the Microbiology and Tumor Biology Center (MTC) at Karolinska Institutet. SKY results are based on 45 metaphases, prepared according to standard cytogenetic procedures. We identified two main populations with a similar pattern of anomalies: a hyperdiploid (2n þ ) stemline and a hypertetraploid (4n þ ) mainline. These populations shared five structural aberrations, including the t(8;14) translocation (Figure 1a depicts representative spectral images), and one numerical chromosomal aberration (Table 1) . In addition, a derivative chromosome, containing material from chromosomes 16 and 17, was specific to the 4n þ population, and was seen in 28 out of 31 cells. In the remaining three metaphases (the sideline), a marker containing only material from chromosome 16 was observed (Table 1) . Interphase FISH using a probe against the centromere of chromosome 8 confirmed the ploidy structure of the Raji cell line (data not shown).
To map more precisely the breakpoints of translocations revealed by SKY and screen for additional gains and losses, we performed CGH using microarrays containing 2600 genomic human bacterial artificial chromosome (BAC) clones with a resolution of approximately 1 Mb. Hybridization and data analysis were performed as described previously. 6 Several copy number changes that were in concordance with the SKY results were identified (data not shown). In addition, we observed a more complex behavior of chromosome 8, resulting in the gain of region 8q11.21-8q22 and the loss of region 8pter-8p11.1. To solve the complex aberrations involving chromosome 8, we performed three-color FISH. Using a combination of probes, we were able to identify two translocations on der(8): a metacentric derivative with duplication of region 8q11.21-8q22, and deletion of region 8pter-8p11.1 involved in translocations with chromosomes 12 and 14 (Figure 1b) .
The combined results of SKY, CGH, and FISH analyses of Raji cells are shown in Table 1 . The origins and breakpoints of all complex rearrangements previously unidentified in G-banding studies have thus been resolved. Interestingly, the gain of chromosome 7 or parts thereof and translocations involving 4q were also frequently mapped in other cell lines established from BL (Karpova et al, manuscript in preparation). Moreover, a comparison of the spectral karyotype of Raji with previously published karyotypes based on G-banding techniques revealed that a limited number of major aberrations were acquired since the original deposition of this cell line ( Table 1 ). The Raji genome thus appears to have remained relatively stable despite decades of continuous cultivation. Macville et al 7 arrived at a similar conclusion following the examination of the cervical carcinoma-derived cell line, HeLa.
